Post-Brexit Divergence Would Harm UK Industry
BGMA Director General Warwick Smith Talks Brexit Implications
On the eve of the UK’s formal exit from the EU on 31 January, BGMA director general Warwick Smith has insisted that it is essential for the UK to stay as close as possible to the current European medicines framework following the conclusion of a transition period that is currently due to expire at the end of 2020.
You may also be interested in...
UK To Diverge On Biosimilar Data Requirements
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.
UK Promises Reduced Trial Burden For Biosimilars
New UK licensing procedures for biosimilars are about to be set out by the MHRA that will reduce the clinical trial data burden for applicants.
EU Parliament Urges Post-Brexit Cooperation
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.